89 related articles for article (PubMed ID: 8185329)
1. [Current status and prospects for targeted therapy for thyroid cancer].
Shimizu K; Mimura T; Harada T; Tanaka S
Gan To Kagaku Ryoho; 1994 May; 21(6):743-8. PubMed ID: 8185329
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody HISL-19 as an immunocytochemical probe for neuroendocrine differentiation. Its application in diagnostic pathology.
Krisch K; Buxbaum P; Horvat G; Krisch I; Neuhold N; Ulrich W; Srikanta S
Am J Pathol; 1986 Apr; 123(1):100-8. PubMed ID: 3515956
[TBL] [Abstract][Full Text] [Related]
3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical, biochemical and immunoelectron microscopic analysis of antigenic proteins on neuroendocrine cell tumors using monoclonal antibody HISL-19.
Shimizu K; Namimatsu S; Kitagawa W; Akasu H; Takatsu K; Sugisaki Y; Tanaka S
J Nippon Med Sch; 2002 Aug; 69(4):365-72. PubMed ID: 12187369
[TBL] [Abstract][Full Text] [Related]
5. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer.
Papewalis C; Wuttke M; Seissler J; Meyer Y; Kessler C; Jacobs B; Ullrich E; Willenberg HS; Schinner S; Baehring T; Scherbaum WA; Schott M
Clin Cancer Res; 2008 Jul; 14(13):4298-305. PubMed ID: 18594013
[TBL] [Abstract][Full Text] [Related]
7. Production of a novel monoclonal antibody, JT-95, which can detect antigen of thyroid carcinoma.
Takeyama H; Hosoya T; Sakurai K; Mori Y; Watanabe M; Kisaki H; Ohno T
Cancer Res; 1996 Apr; 56(8):1817-22. PubMed ID: 8620498
[TBL] [Abstract][Full Text] [Related]
8. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
10. Preparation of a human monoclonal antibody derived from cervical lymph nodes of a patient with anaplastic carcinoma of the thyroid.
Baba M; Kobayashi T; Oka Y; Yagyu T; Tamaki Y; Takeda T; Monden T; Shimano T; Tsuji Y; Murakami H
Hum Antibodies Hybridomas; 1993 Oct; 4(4):181-5. PubMed ID: 8257771
[TBL] [Abstract][Full Text] [Related]
11. [Anaplastic carcinoma of the thyroid: diagnosis and treatment].
Giuffrida D; Lavenia G; Aiello RA; Di Blasi C; Gambera G; Pappalardo A; Petralia G; Ursino M; Failla G
Clin Ter; 2001; 152(4):255-61. PubMed ID: 11725619
[TBL] [Abstract][Full Text] [Related]
12. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer.
Vaccaro A; Chen H; Kunnimalaiyaan M
Anticancer Drugs; 2006 Aug; 17(7):849-53. PubMed ID: 16926634
[TBL] [Abstract][Full Text] [Related]
13. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
[TBL] [Abstract][Full Text] [Related]
14. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro binding of iodinated monoclonal antibody A2B5 to RIN insulinoma cells.
Shimizu K; Reintgen D; Rowley R; Coleman E; Briner W; Seigler H; Eisenbarth GS
Hybridoma; 1983; 2(1):69-77. PubMed ID: 6088390
[TBL] [Abstract][Full Text] [Related]
16. E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar V; Law DA; Ibsen E; Breinberg D; Cass KM; DuBridge RB; Evangelista F; Henshall SM; Hevezi P; Miller JC; Pong M; Powers R; Senter P; Stockett D; Sutherland RL; von Freeden-Jeffry U; Willhite D; Murray R; Afar DE; Ramakrishnan V
Cancer Res; 2003 Oct; 63(19):6387-94. PubMed ID: 14559828
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
[TBL] [Abstract][Full Text] [Related]
18. Antibodies in the therapy of colon cancer.
Welt S; Ritter G
Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
[TBL] [Abstract][Full Text] [Related]
19. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic advances in the management of progressive thyroid cancer.
Woyach JA; Shah MH
Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
